title: Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?
authors.affiliation: University College London Medical School, London, UK. g.dusheiko@medsch.ucl.ac.uk
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Dusheiko
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D003906:Developing Countries; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019259:Lamivudine / Q000008:administration & dosage; D009705:Nucleosides / Q000008:administration & dosage; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011744:Pyrimidinones / Q000008:administration & dosage; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D014611:Vaccination
chemical_list: D000998:Antiviral Agents; D009705:Nucleosides; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D000077712:Telbivudine; D019259:Lamivudine; D013936:Thymidine